Search

Displaying results 6761 - 6770 of 10000 in total
  1. Drug

    Ilodecakin

    go.drugbank.com/drugs/DB06449
    Investigational

  2. Drug

    Odiparcil

    go.drugbank.com/drugs/DB06609
    Investigational

  3. Drug

    Sivifene

    go.drugbank.com/drugs/DB05686
    Investigational

  4. Drug

    Tenamfetamine

    go.drugbank.com/drugs/DB01509
    IllicitInvestigational

    It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem] … An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen.

  5. Drug

    Poly(lactic acid)

    go.drugbank.com/drugs/DB15037
    ApprovedInvestigationalWithdrawn

    Poly(lactic acid) is under investigation in clinical trial NCT00126308 (Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy).

  6. Drug

    Huperzine B

    go.drugbank.com/drugs/DB03348
    Experimental

    Huperzine B is a novel acetylcholinesterase inhibitor.

  7. Drug

    Rexlemestrocel-L

    go.drugbank.com/drugs/DB17606
    Investigational

    It is being investigated in various cardiac conditions, such as chronic heart failure and acute myocardial infarction. … Rexlemestrocel-L is an investigational human bone marrow-derived allogeneic mesenchymal precursor cell (MPC) product.

  8. Drug

    Ertumaxomab

    go.drugbank.com/drugs/DB18923
    Investigational

    Ertumaxomab is under investigation in clinical trial NCT00522457 (Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy).

  9. Drug

    Salix alba bark volatile oil

    go.drugbank.com/drugs/DB14354
    Investigational

    Salix alba bark volatile oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  10. Drug

    Elraglusib

    go.drugbank.com/drugs/DB16047
    Investigational

    Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis).